Harvard researchers found that taking topiramate during pregnancy did not increase the risk of babies developing autism, but CHD Chief Scientific Officer Brian Hooker, Ph.D., questioned the study’s findings.

Topiramate, an antiseizure medication, when taken by pregnant women did not appear to increase the risk of their children developing autism spectrum disorder (ASD), according to the authors of a new study.

However, Brian Hooker, Ph.D., chief scientific officer at Children’s Health Defense (CHD), questioned the study’s findings, and whether the researchers manipulated the data in a way to obfuscate a possible connection.

“This study is fundamentally flawed,” Hooker — who has a child with autism — told The Defender. “It just seems like they designed a study to not find things.”

Researchers at the Harvard T.H. Chan School of Public Health analyzed the health records of mothers with epilepsy who took topiramate, seeking to determine if the drug increased their children’s risk of autism.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.